April #90 : Zeritocracy - by Tim Murphy

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

It Happened In April

Good Morning, HAART Break

Putting On The Ritts

We Interrupt This Program

Wish You Were Here

BABAA Black Sheep

Neg & Pos

The Oral Majority

C No Evil

Sunday Best

Sure Shot

Golden Gates

Condom Man!

Suffering Fools

Milestones

Toys 'R' Us

Bi'er Beware

Research & Derailment

The Secretary

We Got You Covered

Desperate Measures

The Bottom Line

I Want My HIV MD!

B and Thee

Safe Passage

Lord of the Ring

Supercalifragilistic-lacticacidosis!

Protest

On Your Mark

Zeritocracy

To Kiss and Tell

Fantasy Island

Mailbox

Prophet of Boom

Publisher's Letter



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

April 2003

Zeritocracy

by Tim Murphy

Doth the bell toll for Zerit, a.k.a. Bristol-Myers Squibb’s embattled nucleoside analog, d4T? First, it got a high-profile spanking at last year’s world AIDS confab, when a big fed-funded study showed that HIVers who started HAART on a d4T/ddI combo had more lipoatrophy (abnormal fat loss) in  arms and legs than those who started on an AZT/3TC combo. Then, last December —the same month the FDA approved a once-a-day version of Zerit—a study by France’s Agency for AIDSResearch reported that, among d4T-naïves with otherwise-equal time on HAART, roughly half of those on a Crixivan/3TC/d4T combo showed fat loss in the face, limbs and butt after two and a half years, compared to just less than a quarter of those on Crix/3TC/AZT.

This bad news for BMS no doubt delights archrival AZT-maker GlaxoSmith-Kline, which has funded other studies with similar results. But what’s the message for Dick and Jane HIVer? “Let’s face it,” says New York City’s Howard Grossman, MD, “the evidence is pretty overwhelming that d4T seems to be more associated with lipo than the other nukes, especially when combined with PIs.” But he notes that AZT doesn’t get off scot-free for lipo, either—findings that lead Boston’s Cal Cohen, MD, to call the difference between the two drugs “real” but “not huge.” And LA’s Mark Katz, MD, adds that age, years infected, time on meds and all-time CD4 low also factor into lipo risk.

What’s an HIVer to do? “Until GSK and BMS figure out what’s going on,” says Grossman, echoing other docs, “why not avoid both” in favor of less lipo-linked nukes, like 3TC and Viread? And if you just ain’t got a choice? Work with it, says San Fran’s Mary Romeyn, MD: “I’d rather need plastic surgery than an undertaker.”




[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dversescott
    Baltimore
    Maryland


    oceanblue65
    louisiana
    Louisiana


    latinpozdallas
    Dallas
    Texas


    Fergie911
    Chicago
    Illinois
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.